Glecirasib vs JMKX001899

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: KRAS G12C · full Non-Small Cell Lung Cancer pipeline

Glecirasib

Marketed by Allist Pharmaceuticals under a licence from Jacobio Pharmaceuticals

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT05002270 · Phase 1/2 · completed

The study was a small, non-randomized, open-label trial without a comparator, evaluating safety, tumor response, and duration of response. Because results are not posted and the design cannot provide a controlled comparison, it offers limited evidence for glecirasib.

Next expected readout: March 2027 · NCT05288205 (registry estimate)

No aligned efficacy figure on record for this race.

JMKX001899

Developed by HUYABIO International, LLC. under a licence from Jemincare

Phase 3 in Non-Small Cell Lung Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2027 · NCT07242274 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGlecirasibJMKX001899
PFS, median—Trial running · NCT07601048—Trial running · NCT07242274
OS, median—Trial running · NCT07601048—Trial running · NCT07242274
ORR—Trial running · NCT07601048—Trial running · NCT07242274
Duration of response, median—Trial running · NCT07601048—Trial running · NCT07242274

PFS, median

Glecirasib
—Trial running · NCT07601048
JMKX001899
—Trial running · NCT07242274

OS, median

Glecirasib
—Trial running · NCT07601048
JMKX001899
—Trial running · NCT07242274

ORR

Glecirasib
—Trial running · NCT07601048
JMKX001899
—Trial running · NCT07242274

Duration of response, median

Glecirasib
—Trial running · NCT07601048
JMKX001899
—Trial running · NCT07242274
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Glecirasib: no structured comparison results are available for Non-Small Cell Lung Cancer.

JMKX001899: no structured comparison results are available for Non-Small Cell Lung Cancer.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Glecirasib's landscape · JMKX001899's landscape